peoplePerson
Keith T. Flaherty
Led the first trials of BRAF inhibition in melanoma and chairs the NCI-MATCH precision medicine trial.
First author of the 2010 vemurafenib (PLX4032) study and leader of the dabrafenib-trametinib combination work; co-chair of NCI-MATCH.
Role
Director of Clinical Research, Mass General Cancer Center
Institution
Specialisms
MelanomaBRAF and MEK inhibitorsPrecision oncology trials
Profiles
| Title | Journal | Year |
|---|---|---|
| Inhibition of mutated, activated BRAF in metastatic melanoma | New England Journal of Medicine | 2010 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | New England Journal of Medicine | 2012 |
Pages like this
not linked directly; found by shared links- TrialCOMBI-AD
Shares Dabrafenib + trametinib, BRAF, Melanoma.
- ProductCobimetinib
Shares Vemurafenib, BRAF, Small-molecule kinase inhibitors, Melanoma.
- TrialCOLUMBUS
Shares Vemurafenib, BRAF, Melanoma.
- PersonGrant McArthur
Shares Vemurafenib, BRAF, Melanoma.
- PairingBRAF inhibitor + MEK inhibitor
Shares Dabrafenib + trametinib, BRAF, Melanoma.
- TermBRAF V600E mutation
Shares Vemurafenib, BRAF, Melanoma.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Dabrafenib + trametinib, BRAF, Melanoma.
- TrialROAR (anaplastic thyroid cancer cohort)
Shares Dabrafenib + trametinib, BRAF, Small-molecule kinase inhibitors.